Ads
related to: when to treat hyperphosphatemia meaning in pregnancy chart- Phosphate Binder FAQs
Get Answers To Frequently Asked
Phosphate Binder Questions.
- Impact Of High Phosphorus
Learn More About The Impact
Of High Phosphorus Levels.
- Savings Information
Download A Savings Card For A
Phosphate Binder Treatment Option.
- Dialysis Patient Support
Read Helpful Resources & Visit An
Official Phosphate Binder Site.
- Your Guide To Phosphorus
Download The Patient Guide
To Learn More About Phosphorus.
- Phosphate Binder Savings
Learn How Help Is Available
Regardless Of Insurance Coverage.
- Phosphate Binder FAQs
Search results
Results From The WOW.Com Content Network
Hyperphosphatemia. Hyperphosphatemia is an electrolyte disorder in which there is an elevated level of phosphate in the blood. [1] Most people have no symptoms while others develop calcium deposits in the soft tissue. [1] The disorder is often accompanied by low calcium blood levels, which can result in muscle spasms.
Sucroferric oxyhydroxide. Sucroferric oxyhydroxide, sold under the brand name Velphoro, is a non-calcium, iron-based phosphate binder used for the control of serum phosphorus levels in adults with chronic kidney disease (CKD) on haemodialysis (HD) or peritoneal dialysis (PD). [6] It is used in form of chewable tablets.
Sevelamer (rINN) is a phosphate binding medication used to treat hyperphosphatemia in patients with chronic kidney disease. When taken with meals, it binds to dietary phosphate and prevents its absorption. Sevelamer was invented and developed by GelTex Pharmaceuticals. Sevelamer is marketed by Sanofi under the brand names Renagel (sevelamer ...
Erythropoiesis-stimulating agents (ESA) are medications which stimulate the bone marrow to make red blood cells. [1] They are used to treat anemia due to end stage kidney disease, chemotherapy, major surgery, or certain treatments in HIV/AIDS. [1][2] In these situations they decrease the need for blood transfusions. [2]
Nephrocalcinosis, once known as Albright's calcinosis after Fuller Albright, is a term originally used to describe the deposition of poorly soluble calcium salts in the renal parenchyma due to hyperparathyroidism. The term nephrocalcinosis is used to describe the deposition of both calcium oxalate and calcium phosphate. [1]
Based on a survey conducted in 2022, Nephrologists stated that the greatest unmet need in the treatment of hyperphosphatemia with phosphate binders is a lower pill burden and better patient compliance. 1 The global market opportunity for treating hyperphosphatemia is expected to exceed $2.5 billion, with the United States accounting for more ...
Vitamin D deficiency is typically diagnosed by measuring the concentration of the 25-hydroxyvitamin D in the blood, which is the most accurate measure of stores of vitamin D in the body. [1][7][2] One nanogram per millilitre (1 ng/mL) is equivalent to 2.5 nanomoles per litre (2.5 nmol/L). Severe deficiency: <12 ng/mL = <30 nmol/L[2] Deficiency ...
Denial of care in chronic kidney disease treatment and management is a significant issue for minority populations. This can be due to healthcare provider bias, structural barriers, and health insurance coverage disparities. Healthcare provider biases can lead to under-treatment, misdiagnosis, or delayed diagnosis.
Ad
related to: when to treat hyperphosphatemia meaning in pregnancy chart